Adults with Smoldering Multiple Myeloma invited to be in a research study testing the addition of an immunotherapy drug to an immunomodulatory drug.

UVA Tracking #
HSR200035
Principal Investigator
Laahn H Foster
Contact
Sharon Johnson
Contact Email
Contact Phone
434.243.2243
Official Trial Title
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have asymptomatic multiple myeloma, also called smoldering multiple myeloma (SMM). The purpose of this study is to find out if the addition of the immunotherapy drug, daratumumab (also known as Darzalex ®), to the combination of lenalidomide and steroids, may further improve the chances that you will not develop active multiple myeloma and possibly live longer.

If you decide to take part in this study, and are randomly assigned to Group 1, you will get the drugs daratumumab and lenalidomide for up to two years and dexamethasone for the first year. If you decide to take part in this study, and are randomly assigned to Group 2, you will receive the drugs lenalidomide for up to two years and dexamethasone for the first year. After you finish your study treatment, your doctor will continue to follow your condition for up to 15 years and watch you for side effects as well as your overall health.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03937635

Compensation

NA